Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Immuneering Corporation (Nasdaq: IMRX) recently announced its participation in the 22nd Annual Needham Virtual Healthcare Conference on April 19, 2023, from 12:45 - 1:25 pm ET. The presentation will provide insights into the company's pipeline, platform, and business strategy.
Key management participating includes Ben Zeskind, CEO; Scott Barrett, CMO; Brett Hall, CSO; and Mallory Morales, VP of Finance. The event will feature a virtual presentation followed by 1x1 investor meetings. All presentations will be webcast live and archived for 30 days on Immuneering's website.
Immuneering is focused on developing medicines for cancer patients, particularly aiming for a universal-RAS therapy through deep cyclic inhibition of the MAPK pathway. Its lead candidate, IMM-1-104, is currently in Phase 1/2a trials for RAS mutation-related advanced solid tumors.
Positive
- None.
Negative
- None.
News Market Reaction – IMRX
In the trading session that priced this news, IMRX declined 0.88%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will present at the 22nd Annual Needham Virtual Healthcare Conference to discuss the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Scott Barrett, M.D., Chief Medical Officer, Brett Hall, Ph.D., Chief Scientific Officer, and Mallory Morales, CPA, Vice President of Finance, Treasurer.
Format: Virtual Presentation and 1x1 Investor Meetings
Virtual Presentation: April 19 from 12:45 - 1:25 pm ET in Track 1
The presentations will be webcast live and archived for 30 days in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.
About Immuneering Corporation
Immuneering is a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy. The company aims to achieve universal activity through deep cyclic inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneering’s lead product candidate, IMM-1-104, is in a Phase 1/2a study in patients with advanced solid tumors harboring RAS mutations. The company’s development pipeline also includes IMM-6-415, a universal-MAPK program, as well as several early-stage programs. For more information, please visit www.immuneering.com.
Media Contact:
Gina Nugent
Nugent Communications
617-460-3579
gina@nugentcommunications.com
Investor Contacts:
Laurence Watts
Gilmartin Group
619-916-7620
laurence@gilmartinir.com
or
Kiki Patel, PharmD
Gilmartin Group
332-895-3225
kiki@gilmartinir.com
